Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.

Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S, Thielemans K, Schuler G, Coulie PG.

Cancer Res. 2008 May 15;68(10):3931-40. doi: 10.1158/0008-5472.CAN-07-5898.

2.

Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.

Carrasco J, Van Pel A, Neyns B, Lethé B, Brasseur F, Renkvist N, van der Bruggen P, van Baren N, Paulus R, Thielemans K, Boon T, Godelaine D.

J Immunol. 2008 Mar 1;180(5):3585-93.

3.

A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.

Godelaine D, Carrasco J, Brasseur F, Neyns B, Thielemans K, Boon T, Van Pel A.

Cancer Immunol Immunother. 2007 Jun;56(6):753-9. Epub 2006 Nov 10.

PMID:
17096150
4.

CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation.

Carrasco J, Godelaine D, Van Pel A, Boon T, van der Bruggen P.

Blood. 2006 Nov 1;108(9):2897-905. Epub 2006 Jul 20.

5.

Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.

Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T.

Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14631-8. Epub 2004 Sep 27.

6.

Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.

Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A.

J Immunol. 2003 Nov 1;171(9):4893-7.

7.

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, Boon T.

Immunol Rev. 2002 Oct;188:33-42. Review.

PMID:
12445279
8.

A reversible functional defect of CD8+ T lymphocytes involving loss of tetramer labeling.

Demotte N, Colau D, Ottaviani S, Godelaine D, Van Pel A, Boon T, van der Bruggen P.

Eur J Immunol. 2002 Jun;32(6):1688-97.

9.

Competition between CTL narrows the immune response induced by prime-boost vaccination protocols.

Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, Gileadi U, Salio M, Van Pel A, Man S, Bonin E, Liljestrom P, Dunbar PR, Cerundolo V.

J Immunol. 2002 May 1;168(9):4391-8.

10.

Induction of cytolytic T lymphocytes by immunization of mice with an adenovirus containing a mouse homolog of the human MAGE-A genes.

Van Pel A, De Plaen E, Duffour MT, Warnier G, Uyttenhove C, Perricaudet M, Boon T.

Cancer Immunol Immunother. 2001 Jan;49(11):593-602.

PMID:
11225990
11.

Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope.

Wölfel C, Drexler I, Van Pel A, Thres T, Leister N, Herr W, Sutter G, Huber C, Wölfel T.

Int J Cancer. 2000 Nov 1;88(3):432-8.

12.

Identification of a novel HLA-Cw*05 allele, Cw*0503.

Huang LQ, Boon T, Van Pel A.

Tissue Antigens. 2000 May;55(5):473-4.

PMID:
10885573
13.

A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes.

Morel S, Ooms A, Van Pel A, Wölfel T, Brichard VG, van der Bruggen P, Van den Eynde BJ, Degiovanni G.

Int J Cancer. 1999 Dec 10;83(6):755-9.

14.

Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.

Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T, Van Pel A.

J Immunol. 1999 Jun 1;162(11):6849-54.

15.

Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815.

Bilsborough J, Van Pel A, Uyttenhove C, Boon T, Van den Eynde BJ.

J Immunol. 1999 Mar 15;162(6):3534-40.

16.

Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.

Romero P, Gervois N, Schneider J, Escobar P, Valmori D, Pannetier C, Steinle A, Wolfel T, Lienard D, Brichard V, van Pel A, Jotereau F, Cerottini JC.

J Immunol. 1997 Sep 1;159(5):2366-74.

PMID:
9278327
17.

Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes.

De Plaen E, Lurquin C, Lethé B, van der Bruggen P, Brichard V, Renauld JC, Coulie P, Van Pel A, Boon T.

Methods. 1997 Jun;12(2):125-42. Review.

PMID:
9184377
18.

Antigens recognized by T-lymphocytes on human tumours.

Coulie PG, Van den Eynde BJ, van der Bruggen P, Van Pel A, Boon T.

Biochem Soc Trans. 1997 May;25(2):544-8. Review. No abstract available.

PMID:
9191153
19.

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene.

Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethé B, Jotereau F, Boon T.

J Exp Med. 1996 Mar 1;183(3):1173-83.

20.

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.

Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL Jr, Boon T, Hunt DF, Engelhard VH.

J Exp Med. 1996 Feb 1;183(2):527-34.

21.

A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes.

Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B, Wölfel T, Boon T, Lethé B.

Eur J Immunol. 1996 Jan;26(1):224-30.

PMID:
8566071
22.

CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide.

Grohmann U, Bianchi R, Fioretti MC, Fallarino F, Binaglia L, Uyttenhove C, Van Pel A, Boon T, Puccetti P.

Eur J Immunol. 1995 Oct;25(10):2797-802.

PMID:
7589074
23.

Genes coding for tumor antigens recognized by cytolytic T lymphocytes.

Van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethé B, van den Eynde B, Uyttenhove C, Renauld JC, Boon T.

Immunol Rev. 1995 Jun;145:229-50. Review. No abstract available.

PMID:
7590828
24.
25.

Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815.

Brichard VG, Warnier G, Van Pel A, Morlighem G, Lucas S, Boon T.

Eur J Immunol. 1995 Mar;25(3):664-71.

PMID:
7705394
26.

An intracisternal A-particle sequence codes for an antigen recognized by syngeneic cytolytic T lymphocytes on a mouse spontaneous leukemia.

de Bergeyck V, De Plaen E, Chomez P, Boon T, Van Pel A.

Eur J Immunol. 1994 Sep;24(9):2203-12.

PMID:
8088336
27.

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, Renauld JC, Boon T.

J Exp Med. 1994 Jul 1;180(1):35-42.

28.

Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity.

Puccetti P, Bianchi R, Fioretti MC, Ayroldi E, Uyttenhove C, Van Pel A, Boon T, Grohmann U.

Eur J Immunol. 1994 Jun;24(6):1446-52.

PMID:
8206103
29.

Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes.

Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde KH, Boon T.

Eur J Immunol. 1994 Mar;24(3):759-64.

PMID:
8125142
30.

Tumor antigens recognized by T lymphocytes.

Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A.

Annu Rev Immunol. 1994;12:337-65. Review.

PMID:
8011285
31.

Defined antigens recognized by T lymphocytes on human tumors.

Coulie PG, Van Pel A.

Curr Opin Oncol. 1993 Nov;5(6):1043-8. Review.

PMID:
8305537
32.

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, Coulie P, Boon T.

J Exp Med. 1993 Aug 1;178(2):489-95.

33.

Genes coding for tumor antigens recognized by human cytolytic T lymphocytes.

Coulie PG, Weynants P, Lehmann F, Herman J, Brichard V, Wölfel T, Van Pel A, De Plaen E, Brasseur F, Boon T.

J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):104-9. Review.

PMID:
8280701
34.
35.

The tum- antigens P91A and P198 derive from proteins located in the cytosolic compartment of cells.

Verlant V, Amar-Costesec A, Godelaine D, Turu C, Van Pel A, De Plaen E, Dautry-Varsat A, Beaufay H.

Eur J Immunol. 1993 Jul;23(7):1727-30.

PMID:
8325344
36.

Tum- mutation P35B generates the MHC-binding site of a new antigenic peptide.

Szikora JP, Van Pel A, Boon T.

Immunogenetics. 1993;37(2):135-8.

PMID:
8423052
37.

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T.

J Exp Med. 1992 Nov 1;176(5):1453-7.

38.

Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific for an immunogenic tumor variant.

Wallny HJ, Deres K, Faath S, Jung G, Van Pel A, Boon T, Rammensee HG.

Int Immunol. 1992 Oct;4(10):1085-90.

PMID:
1283332
39.

Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide.

Lethé B, van den Eynde B, van Pel A, Corradin G, Boon T.

Eur J Immunol. 1992 Sep;22(9):2283-8.

PMID:
1381312
40.

Efficient expression of tum- antigen P91A by transfected subgenic fragments.

Chomez P, De Plaen E, Van Pel A, De Smet C, Szikora JP, Lurquin C, Lebacq-Verheyden AM, Boon T.

Immunogenetics. 1992;35(4):241-52.

PMID:
1541484
41.

Identification of tumour rejection antigens recognized by T lymphocytes.

Boon T, De Plaen E, Lurquin C, Van den Eynde B, van der Bruggen P, Traversari C, Amar-Costesec A, Van Pel A.

Cancer Surv. 1992;13:23-37. Review.

PMID:
1423324
42.

Tum- antigens, TSTA, and T cell immune surveillance.

Van Pel A, Warnier G, Van den Eynde B, Lethé B, Lurquin C, Boon T.

Ann N Y Acad Sci. 1991 Dec 30;636:43-51. Review. No abstract available.

PMID:
1793230
43.

The identification of tyrosine as a common key residue in unrelated H-2Kd restricted antigenic peptides.

Maryanski JL, Romero P, Van Pel A, Boon T, Salemme FR, Cerottini JC, Corradin G.

Int Immunol. 1991 Oct;3(10):1035-42.

PMID:
1721832
44.

The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.

Van den Eynde B, Lethé B, Van Pel A, De Plaen E, Boon T.

J Exp Med. 1991 Jun 1;173(6):1373-84.

45.

Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide.

Sibille C, Chomez P, Wildmann C, Van Pel A, De Plaen E, Maryanski JL, de Bergeyck V, Boon T.

J Exp Med. 1990 Jul 1;172(1):35-45.

46.

Structure of the gene of tum- transplantation antigen P35B: presence of a point mutation in the antigenic allele.

Szikora JP, Van Pel A, Brichard V, André M, Van Baren N, Henry P, De Plaen E, Boon T.

EMBO J. 1990 Apr;9(4):1041-50.

47.

Tum- transplantation antigens, point mutations, and antigenic peptides: a model for tumor-specific transplantation antigens?

Boon T, Van Pel A, De Plaen E.

Cancer Cells. 1989 Sep;1(1):25-8. Review. No abstract available.

PMID:
2701358
48.

Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells.

Lurquin C, Van Pel A, Mariamé B, De Plaen E, Szikora JP, Janssens C, Reddehase MJ, Lejeune J, Boon T.

Cell. 1989 Jul 28;58(2):293-303.

PMID:
2568889
49.

Cloning and characterization of genes coding for tum- transplantation antigens.

Boon T, Szikora JP, De Plaen E, Wölfel T, Van Pel A.

J Autoimmun. 1989 Jun;2 Suppl:109-14. No abstract available.

PMID:
2789058

Supplemental Content

Loading ...
Support Center